Company
Seoul, OS
Every investor coverage indicates participated in a round Korea Investment Partners raised.
Companies Korea Investment Partners acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Korea Investment Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.
Also GBS Ventures
Cell Innovation Partners invested A$1 million in Sydney biotech Elastagen within a second close of its A$14 million Series B, with AMOREPACIFIC Ventures, Korea Investment Partners and the Wellcome Trust also joining the round.
Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.